Related Experiment Videos
MUC1 and cancer
J Taylor-Papadimitriou1, J Burchell, D W Miles
1Imperial Cancer Research Fund, Breast Cancer Biology Group, Guy's Hospital, London, UK.
Biochimica Et Biophysica Acta
|November 26, 1999
Summary
MUC1, a cancer-associated molecule, differs from normal mucin due to altered glycosylation. These changes expose unique epitopes, making MUC1 a target for cancer immunotherapy.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- MUC1 is a membrane mucin identified by antibodies targeting epithelial cells and cancers.
- Its extracellular domain consists of conserved amino acid repeats, with glycosylation sites influencing antigenicity.
Purpose of the Study:
- To investigate the antigenic differences between normal and cancer-associated MUC1.
- To explore the potential of MUC1 as a target for cancer immunotherapy.
Main Methods:
- Gene cloning to analyze MUC1 structure.
- Glycosylation analysis of MUC1 from normal and cancerous breast tissue.
- Review of immune responses and clinical studies involving MUC1.
Main Results:
- MUC1 from normal breast tissue has complex, core 2-based O-glycans.
- Breast cancer MUC1 exhibits mainly core 1-based O-glycans, exposing protein epitopes.
- Novel carbohydrate epitopes are present on cancer-associated MUC1, rendering it antigenically distinct.
Conclusions:
- MUC1's altered glycosylation in cancer creates unique epitopes, distinguishing it from normal MUC1.
- These antigenic differences support MUC1's role as a target for cancer immunotherapy.
- The role of MUC1 carbohydrates in immune responses warrants further investigation.